Orion Market Research Pvt. Ltd. info@omrglobal.com +91 780-304-0404
Help Center
Careers
Contact

Imatinib Drug Market

Imatinib Drugs Market Size, Share & Trends Analysis Report, By Product Type (Branded Imatinib, Generic Imatinib), By Dosage Form (Tablets, Capsules), By Application (Chronic Myeloid Leukemia (CML), Gastrointestinal Stromal Tumors (GIST), Acute Lymphoblastic Leukemia (Ph+ ALL), Dermatofibrosarcoma Protuberans (DFSP), Other Rare Indications), Forecast Period (2026-2035)

Published: May 2026 | Report Code: OMR2025552 | Category : Pharmaceuticals | Delivery Format: /

Industry Overview

Imatinib drugs market size was valued at $1.80 billion in 2025 and is projected to reach $2.52 billion by 2035, growing at a CAGR of 4.3% between 2026 and 2035. The market consists of targeted oncology drugs primarily used in the treatment of chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST). Imatinib plays a critical role in inhibiting tyrosine kinase activity, improving survival rates and reducing disease progression in cancer patients. A key driver supporting market growth is the rising global burden of cancer and increasing adoption of targeted therapies. According to the World Health Organization, cancer accounted for nearly 10 million deaths globally, with leukemia representing a significant share of cases. Additionally, the European Federation of Pharmaceutical Industries and Associations highlights increasing investments in oncology drug development and production, supporting the availability of advanced cancer treatments. The expansion of generic drug manufacturing and improved healthcare access across emerging economies is further strengthening market growth. Imatinib drugs are widely used across hospitals and oncology clinics, supporting long-term treatment and disease management.

Market Dynamics

Rising Cancer Prevalence Driving Market Growth

The increasing prevalence of cancer and the growing adoption of targeted therapies are major factors driving the imatinib drugs market. Governments and healthcare organizations are focusing on improving cancer diagnosis and treatment accessibility. According to the World Health Organization, leukemia continues to be a major health concern globally, driving demand for effective treatment solutions such as imatinib. Pharmaceutical companies are investing in expanding oncology portfolios and improving production capabilities between 2023 and 2026 to meet rising demand. Additionally, regulatory support for generic drug approvals is increasing accessibility and affordability of imatinib drugs worldwide.

Pricing Pressure and Generic Competition Limiting Market Growth

Despite strong demand, the market faces challenges due to pricing pressure and increasing competition from generic manufacturers. The availability of low-cost generic imatinib drugs has significantly reduced pricing levels, affecting revenue growth. According to the Organisation for Economic Co-operation and Development, rising healthcare cost pressures are encouraging the adoption of generic drugs, impacting branded drug sales. Furthermore, regulatory requirements and manufacturing complexities add to operational challenges. To address these issues, companies are focusing on improving manufacturing efficiency, expanding into emerging markets, and developing differentiated oncology products.

Market Segmentation

  • Based on the product type, the market is segmented into branded imatinib and generic imatinib.
  • Based on the dosage form, the market is segmented into tablets and capsules.
  • based on the application, the market is segmented into chronic myeloid leukemia (CML), gastrointestinal stromal tumors (GIST), acute lymphoblastic leukemia (Ph+ ALL), dermatofibrosarcoma protuberans (DFSP), and other rare indications.

Generic Imatinib Segment Leads the Market

The generic imatinib segment holds a dominant position in the market due to its affordability and widespread adoption across global healthcare systems. The expiration of patents for branded imatinib has enabled multiple pharmaceutical companies to introduce generic versions, significantly reducing treatment costs. Governments and healthcare providers are increasingly promoting generic drug usage to improve patient access to essential oncology treatments. The expansion of generic manufacturing capabilities and distribution networks between 2022 and 2026 is further supporting segment growth.

Chronic Myeloid Leukemia (CML) Segment to Record Strong Growth

The CML segment is expected to witness strong growth due to increasing diagnosis rates and the effectiveness of imatinib as a first-line therapy. Advances in diagnostic technologies and growing awareness about early cancer detection are contributing to higher treatment adoption. Additionally, investments in healthcare infrastructure and oncology research are supporting the expansion of targeted therapies. Pharmaceutical companies are focusing on improving treatment accessibility and enhancing patient outcomes, driving growth in this segment.

Regional Outlook

The global imatinib drugs market is geographically segmented into North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa and Latin America).

United States Leads the Market

The United States dominates the imatinib drugs market due to advanced healthcare infrastructure and strong adoption of oncology therapies. According to the U.S. Food and Drug Administration, increasing approvals of oncology drugs and supportive regulatory frameworks are driving market growth. High healthcare expenditure and well-established pharmaceutical industry further strengthen the market position.

China to Record Strong Growth

China is expected to witness strong growth due to increasing investments in pharmaceutical manufacturing and healthcare infrastructure. According to the International Trade Centre, China’s expanding pharmaceutical exports and production capabilities are supporting the growth of oncology drugs. Government initiatives aimed at improving healthcare access are further driving demand for imatinib drugs.

Competitive Landscape

The imatinib drugs market is highly competitive, characterized by strong presence of both branded and generic pharmaceutical companies. Leading players such as Novartis AG, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Viatris Inc., and Dr. Reddy’s Laboratories Ltd. are focusing on expanding product portfolios, improving manufacturing capabilities, and strengthening global distribution networks to enhance market competitiveness.

Recent Developments

  • In March 2026, Teva secured U.S. FDA approval for PONLIMSI™ (denosumab-adet), gaining massive biosimilar momentum. Additionally, the company announced the acceptance of a dual filing for its biosimilar candidate to Xolair® (omalizumab), pushing forward its aggressive pivot-to-growth strategy.
  • In March 2026, Viatris secured approval in Japan for Effexor for adults with Generalized Anxiety Disorder (GAD). This follows the company's full-year 2025 earnings reporting total revenues of $14.3 billion and the completion of an enterprise-wide strategic review to deliver $650 million in total cost savings over the next three years.

The Report Covers

  • Market value data analysis of 2025 and forecast to 2035.
  • Annualised market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global imatinib drugs market. Based on the availability of data, information related to new products and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying ‘who-stands-where’ in the market.

 

  1. Report Summary
  • Current Industry Analysis and Growth Potential Outlook
  • Global Imatinib Drugs Market Sales Analysis – Product Type | Dosage Form | Dosage | Application ($ Million)
  • Imatinib Drugs Market Sales Performance of Top Countries

1.1 Research Methodology

  • Primary Research Approach
  • Secondary Research Approach

1.2 Market Snapshot

  1. Market Overview and Insights

2.1 Scope of the Study

2.2 Analyst Insight & Current Market Trends

2.2.1 Key Imatinib Drugs Market Trends
2.2.2 Market Recommendations

2.3 Porter's Five Forces Analysis for the Imatinib Drugs Market

2.3.1 Competitive Rivalry
2.3.2 Threat of New Entrants
2.3.3 Bargaining Power of Suppliers
2.3.4 Bargaining Power of Buyers
2.3.5 Threat of Substitutes

  1. Market Determinants

3.1 Market Drivers

3.1.1 Drivers For Global Imatinib Drugs Market: Impact Analysis

3.2 Market Pain Points and Challenges

3.2.1 Restraints For Global Imatinib Drugs Market: Impact Analysis

3.3 Market Opportunities

3.3.1 Opportunities For Global Imatinib Drugs Market: Impact Analysis

  1. Competitive Landscape

4.1 Competitive Dashboard – Imatinib Drugs Market Revenue and Share by Manufacturers

  • Imatinib Drugs Product Comparison Analysis
  • Top Market Player Ranking Matrix

4.2 Key Company Analysis

4.2.1 Novartis AG

4.2.1.1 Overview

4.2.1.2 Product Portfolio

4.2.1.3 Financial Analysis
4.2.1.4 SWOT Analysis
4.2.1.5 Business Strategy

4.2.2 Teva Pharmaceutical Industries Ltd.

4.2.2.1 Overview
4.2.2.2 Product Portfolio
4.2.2.3 Financial Analysis
4.2.2.4 SWOT Analysis
4.2.2.5 Business Strategy

4.2.3 Sun Pharmaceutical Industries Ltd.

4.2.3.1 Overview
4.2.3.2 Product Portfolio
4.2.3.3 Financial Analysis
4.2.3.4 SWOT Analysis
4.2.3.5 Business Strategy

4.2.4 Viatris Inc.

4.2.4.1 Overview
4.2.4.2 Product Portfolio
4.2.4.3 Financial Analysis
4.2.4.4 SWOT Analysis
4.2.4.5 Business Strategy

4.2.5 Dr. Reddy’s Laboratories Ltd.

4.2.5.1 Overview
4.2.5.2 Product Portfolio
4.2.5.3 Financial Analysis
4.2.5.4 SWOT Analysis
4.2.5.5 Business Strategy

4.3 Top Winning Strategies by Market Players

4.3.1 Merger and Acquisition
4.3.2 Product Launch
4.3.3 Partnership And Collaboration

  1. Global Imatinib Drugs Market Sales Analysis by Product Type ($ Million)

5.1 Branded Imatinib
5.2 Generic Imatinib

  1. Global Imatinib Drugs Market Sales Analysis by Dosage Form ($ Million)

6.1 Tablets
6.2 Capsules

  1. Global Imatinib Drugs Market Sales Analysis by Application ($ Million)

7.1 Chronic Myeloid Leukemia (CML)
7.2 Gastrointestinal Stromal Tumors (GIST)
7.3 Acute Lymphoblastic Leukemia (Ph+ ALL)
7.4 Dermatofibrosarcoma Protuberans (DFSP)
7.5 Other Rare Indications

  1. Regional Analysis

8.1 North American Imatinib Drugs Market Sales Analysis – Product Type | Dosage Form | Dosage | Application ($ Million)

8.1.1 United States

8.1.2 Canada

8.2 European Imatinib Drugs Market Sales Analysis – Product Type | Dosage Form | Dosage | Application ($ Million)

8.2.1 UK
8.2.2 Germany
8.2.3 Italy
8.2.4 Spain
8.2.5 France
8.2.6 Russia
8.2.7 Rest of Europe

8.3 Asia-Pacific Imatinib Drugs Market Sales Analysis – Product Type | Dosage Form | Dosage | Application ($ Million)

8.3.1 China

8.3.2 Japan
8.3.3 South Korea
8.3.4 India
8.3.5 Australia & New Zealand
8.3.6 ASEAN Countries
8.3.7 Rest of Asia-Pacific

8.4 Rest of the World Imatinib Drugs Market Sales Analysis – Product Type | Dosage Form | Dosage | Application ($ Million)

8.4.1 Latin America

8.4.2 Middle East and Africa

  1. Company Profiles

9.1 Alembic Pharmaceuticals Ltd.

9.1.1 Quick Facts

9.1.2 Company Overview

9.1.3 Product Portfolio
9.1.4 Business Strategies

9.2 Alkem Laboratories Ltd.
9.2.1 Quick Facts
9.2.2 Company Overview
9.2.3 Product Portfolio
9.2.4 Business Strategies

9.3 Apotex Inc.
9.3.1 Quick Facts
9.3.2 Company Overview
9.3.3 Product Portfolio
9.3.4 Business Strategies

9.4 Aurobindo Pharma Ltd.
9.4.1 Quick Facts
9.4.2 Company Overview
9.4.3 Product Portfolio
9.4.4 Business Strategies

9.5 Camber Pharmaceuticals, Inc.
9.5.1 Quick Facts
9.5.2 Company Overview
9.5.3 Product Portfolio
9.5.4 Business Strategies

9.6 Celon Laboratories Private Limited
9.6.1 Quick Facts
9.6.2 Company Overview
9.6.3 Product Portfolio
9.6.4 Business Strategies

9.7 Cipla Inc.
9.7.1 Quick Facts
9.7.2 Company Overview
9.7.3 Product Portfolio
9.7.4 Business Strategies

9.8 Glenmark Pharmaceuticals Ltd.
9.8.1 Quick Facts
9.8.2 Company Overview
9.8.3 Product Portfolio
9.8.4 Business Strategies

9.9 Hetero Drugs Limited
9.9.1 Quick Facts
9.9.2 Company Overview
9.9.3 Product Portfolio
9.9.4 Business Strategies

9.10 Hikma Pharmaceuticals PLC
9.10.1 Quick Facts
9.10.2 Company Overview
9.10.3 Product Portfolio
9.10.4 Business Strategies

9.11 Intas Pharmaceuticals Ltd.
9.11.1 Quick Facts
9.11.2 Company Overview
9.11.3 Product Portfolio
9.11.4 Business Strategies

9.12 Lupin Limited
9.12.1 Quick Facts
9.12.2 Company Overview
9.12.3 Product Portfolio
9.12.4 Business Strategies

9.13 Natco Pharma Ltd.
9.13.1 Quick Facts
9.13.2 Company Overview
9.13.3 Product Portfolio
9.13.4 Business Strategies

9.14 S P Accure Labs Private Limited
9.14.1 Quick Facts
9.14.2 Company Overview
9.14.3 Product Portfolio
9.14.4 Business Strategies

9.15 Sandoz International GmbH
9.15.1 Quick Facts
9.15.2 Company Overview
9.15.3 Product Portfolio
9.15.4 Business Strategies

9.16 Strides Pharma Science Ltd.
9.16.1 Quick Facts
9.16.2 Company Overview
9.16.3 Product Portfolio
9.16.4 Business Strategies

9.17 Thermdose Pharma Pvt. Ltd.
9.17.1 Quick Facts
9.17.2 Company Overview
9.17.3 Product Portfolio
9.17.4 Business Strategies

9.18 Torrent Pharmaceuticals Ltd.
9.18.1 Quick Facts
9.18.2 Company Overview
9.18.3 Product Portfolio
9.18.4 Business Strategies

9.19 Vannsh Life Sciences Private Limited
9.19.1 Quick Facts
9.19.2 Company Overview
9.19.3 Product Portfolio
9.19.4 Business Strategies

9.20 Zydus Lifesciences Ltd.
9.20.1 Quick Facts
9.20.2 Company Overview
9.20.3 Product Portfolio
9.20.4 Business Strategies

NA1. Global Imatinib Drug Market Research and Analysis by Product Type, 2025–2035 ($ Million) 

2. Global Branded Imatinib Drug Market Research and Analysis by Region, 2025–2035 ($ Million) 

3. Global Generic Imatinib Drug Market Research and Analysis by Region, 2025–2035 ($ Million) 

4. Global Imatinib Drug Market Research and Analysis by Dosage Form, 2025–2035 ($ Million) 

5. Global Tablets Imatinib Drug Market Research and Analysis by Region, 2025–2035 ($ Million) 

6. Global Capsules Imatinib Drug Market Research and Analysis by Region, 2025–2035 ($ Million) 

7. Global Imatinib Drug Market Research and Analysis by Application, 2025–2035 ($ Million) 

8. Global Imatinib Drug for Chronic Myeloid Leukaemia (CML) Market Research and Analysis by Region, 2025–2035 ($ Million) 

9. Global Imatinib Drug for Gastrointestinal Stromal Tumours (GIST) Market Research and Analysis by Region, 2025–2035 ($ Million) 

10. Global Imatinib Drug for Acute Lymphoblastic Leukaemia (Ph+ ALL) Market Research and Analysis by Region, 2025–2035 ($ Million) 

11. Global Imatinib Drug for Dermatofibrosarcoma Protuberans (DFSP) Market Research and Analysis by Region, 2025–2035 ($ Million) 

12. Global Imatinib Drug for Other Rare Indications Market Research and Analysis by Region, 2025–2035 ($ Million) 

13. Global Imatinib Drug Market Research and Analysis by Region, 2025–2035 ($ Million) 

14. North America Imatinib Drug Market Research and Analysis by Country, 2025–2035 ($ Million) 

15. North America Imatinib Drug Market Research and Analysis by Product Type, 2025–2035 ($ Million) 

16. North America Imatinib Drug Market Research and Analysis by Dosage Form, 2025–2035 ($ Million) 

17. North America Imatinib Drug Market Research and Analysis by Application, 2025–2035 ($ Million) 

18. Europe Imatinib Drug Market Research and Analysis by Country, 2025–2035 ($ Million) 

19. Europe Imatinib Drug Market Research and Analysis by Product Type, 2025–2035 ($ Million) 

20. Europe Imatinib Drug Market Research and Analysis by Dosage Form, 2025–2035 ($ Million) 

21. Europe Imatinib Drug Market Research and Analysis by Application, 2025–2035 ($ Million) 

22. Asia-Pacific Imatinib Drug Market Research and Analysis by Country, 2025–2035 ($ Million) 

23. Asia-Pacific Imatinib Drug Market Research and Analysis by Product Type, 2025–2035 ($ Million) 

24. Asia-Pacific Imatinib Drug Market Research and Analysis by Dosage Form, 2025–2035 ($ Million) 

25. Asia-Pacific Imatinib Drug Market Research and Analysis by Application, 2025–2035 ($ Million) 

26. Rest of the World Imatinib Drug Market Research and Analysis by Region, 2025–2035 ($ Million) 

27. Rest of the World Imatinib Drug Market Research and Analysis by Product Type, 2025–2035 ($ Million) 

28. Rest of the World Imatinib Drug Market Research and Analysis by Dosage Form, 2025–2035 ($ Million) 

29. Rest of the World Imatinib Drug Market Research and Analysis by Application, 2025–2035 ($ Million) 

1. Global Imatinib Drug Market Share by Product Type, 2025 Vs 2035 (%) 

2. Global Branded Imatinib Drug Market Share by Region, 2025 Vs 2035 (%) 

3. Global Generic Imatinib Drug Market Share by Region, 2025 Vs 2035 (%) 

4. Global Imatinib Drug Market Share by Dosage Form, 2025 Vs 2035 (%) 

5. Global Tablets Imatinib Drug Market Share by Region, 2025 Vs 2035 (%) 

6. Global Capsules Imatinib Drug Market Share by Region, 2025 Vs 2035 (%) 

7. Global Imatinib Drug Market Share by Application, 2025 Vs 2035 (%) 

8. Global Imatinib Drug for Chronic Myeloid Leukaemia (CML) Market Share by Region, 2025 Vs 2035 (%) 

9. Global Imatinib Drug for Gastrointestinal Stromal Tumours (GIST) Market Share by Region, 2025 Vs 2035 (%) 

10. Global Imatinib Drug for Acute Lymphoblastic Leukaemia (Ph+ ALL) Market Share by Region, 2025 Vs 2035 (%) 

11. Global Imatinib Drug for Dermatofibrosarcoma Protuberans (DFSP) Market Share by Region, 2025 Vs 2035 (%) 

12. Global Imatinib Drug for Other Rare Indications Market Share by Region, 2025 Vs 2035 (%) 

13. Global Imatinib Drug Market Share by Region, 2025 Vs 2035 (%) 

14. US Imatinib Drug Market Size, 2025–2035 ($ Million) 

15. Canada Imatinib Drug Market Size, 2025–2035 ($ Million) 

16. UK Imatinib Drug Market Size, 2025–2035 ($ Million) 

17. France Imatinib Drug Market Size, 2025–2035 ($ Million) 

18. Germany Imatinib Drug Market Size, 2025–2035 ($ Million) 

19. Italy Imatinib Drug Market Size, 2025–2035 ($ Million) 

20. Spain Imatinib Drug Market Size, 2025–2035 ($ Million) 

21. Russia Imatinib Drug Market Size, 2025–2035 ($ Million) 

22. India Imatinib Drug Market Size, 2025–2035 ($ Million) 

23. China Imatinib Drug Market Size, 2025–2035 ($ Million) 

24. Japan Imatinib Drug Market Size, 2025–2035 ($ Million) 

25. South Korea Imatinib Drug Market Size, 2025–2035 ($ Million) 

26. Australia & New Zealand Imatinib Drug Market Size, 2025–2035 ($ Million) 

27. ASEAN Imatinib Drug Market Size, 2025–2035 ($ Million) 

28. Rest of Asia-Pacific Imatinib Drug Market Size, 2025–2035 ($ Million) 

29. Latin America Imatinib Drug Market Size, 2025–2035 ($ Million) 

30. Middle East & Africa Imatinib Drug Market Size, 2025–2035 ($ Million) 

Choose License Type
    On Discount
Enterprise Custom
  • Printable version
  • No restriction to number of users within the company
CONTACT SALES

100%
Secured Payment

Why buy from us?
  • Covers more than 15 major industries, which are further segmented into 90+ sectors
  • 65% of our clients are loyal customers
  • 120+ countries are covered in analysis
  • currently servicing 1000+ customers globally
  • 100+ paid data sources mined to research
  • Our expert team will assist you with all research need and customization
  • Our expert research analyst will resolve your every query before and after purchasing the report
Related Reports

FAQS

The size of the Imatinib Drugs Market in 2025 is estimated to be around $1.80 billion.
United States holds the largest share in the Imatinib Drugs Market.
Leading players in the Imatinib Drugs Market Includes Novartis AG, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Viatris Inc., and Dr. Reddy’s Laboratories Ltd., among others.
The Imatinib Drugs Market is expected to grow at a CAGR of 4.3% from 2026 to 2035.
Rising prevalence of chronic myeloid leukemia and gastrointestinal stromal tumors, increasing adoption of targeted cancer therapies, and growing access to oncology treatments are driving the Imatinib Drugs Market growth.